Sponsored by Bio Ascend

At the Oncology Nursing Society’s (ONS) 44th Annual Congress, a satellite symposium titled “Patient and Nurse Perspectives on the Use of PARP Inhibitors for Ovarian Cancer: Strategies for Maximizing Patient Outcomes” was held. This program was chaired by Paula J. Anastasia, RN, MN, AOCN from the University of California, Los Angeles School of Medicine. Ms. Anastasia opened the symposium discussing patient selection for PARP inhibitor therapy, and how to align patients with the proper type of therapy. Kathleen Moore, MD from the University of Oklahoma Health Sciences Center reviewed some of the clinical data of currently approved PARP inhibitors. Kimberly Halla, MSN, FNP-C from Arizona Oncology addressed strategies for managing patients receiving PARP inhibitors, including how to address adverse events that may occur with PARP inhibitor therapy. This symposium also included the unique perspective of a patient with ovarian cancer, who shared her story and her decision to stay on maintenance therapy.

After the symposium, Paula Anastasia and Kimberly Halla convened for a recorded discussion to highlight the most clinically relevant data presented during the symposium. Their recorded conversation is a CNE-certified Expert Insights program which covers how information presented at the symposium affects current and future strategies for managing patients with ovarian cancer.

If you would like to access the CNE-certified Expert Insights enduring activity, please visit www.BioAscend.com/ONS. To view a non-accredited recording of the live symposium with downloadable slides, please visit www.BioAscend.com/ONSslides.

0